Stockscreener 앱 받기
6.12
5.34%
0.31
전일 마감가:
$5.81
열려 있는:
$5.81
하루 거래량:
98,679
Relative Volume:
0.38
시가총액:
$6.64M
수익:
$72,100
순이익/손실:
$-4.84M
주가수익비율:
-0.8207
EPS:
-7.4566
순현금흐름:
$-3.84M
1주 성능:
-4.97%
1개월 성능:
+5.24%
6개월 성능:
+6.00%
1년 성능:
-31.13%
1일 변동 폭
$5.6801
$6.50
1주일 범위
$5.6801
$6.75
52주 변동 폭
$3.315
$15.15
Silo Pharma Inc Stock (SILO) Company Profile
명칭
Silo Pharma Inc
전화
(718) 400-9031
주소
677 N. WASHINGTON BLVD, SARASOTA
Compare SILO vs MOBBW, SHMD, GOODO, PSNYW, DWLD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SILO
SILO PHARMA INC
|
1.71 | 17.96M | 0 | 0 | 0 | 0.00 |
MOBBW
Mobilicom Limited Warrants
|
2.38 | 3.16B | 0 | 0 | 0 | 0.00 |
SHMD
Schmid Group N V
|
6.54 | 425.01M | 52.15M | -21.46M | 0 | -0.4675 |
GOODO
Gladstone Commercial Corporation
|
20.26 | 372.90M | 0 | 0 | 0 | 0.00 |
PSNYW
Polestar Automotive Holding Uk
|
2.909 | 269.09M | 2.07B | -1.42B | -1.37B | -0.6765 |
DWLD
Davis Select Worldwide ETF
|
46.61 | 0 | 0 | 0 | 0 | 0.00 |
Silo Pharma Inc 주식(SILO)의 최신 뉴스
Silo Pharma regains compliance with Nasdaq min bid price requirement - TipRanks
Silo Pharma Regains Nasdaq Compliance and Advances PTSD Drug SPC-15 Toward Clinical Trials - Minichart
Silo Pharma Regains Nasdaq Compliance, Stabilizing Listing Status - TipRanks
Silo Pharma regains Nasdaq minimum bid price compliance, ticker SILO - TradingView
Silo Pharma (SILO) restores Nasdaq minimum bid price compliance status - Stock Titan
Silo Pharma (SILO) to vote on director slate, auditor and stock increase at Aug 14 meeting - Stock Titan
Silo Pharma Says it Regained Compliance With Nasdaq's Minimum Bid Price Requirement - marketscreener.com
Silo Pharma Regains Compliance With Nasdaq Minimum Bid Price Requirement - TradingView
Silo Pharma clears Nasdaq’s bid-price test; stock stays listed - Stock Titan
Silo Pharma Inc (SILO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Silo Pharma Inc (SILO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Silo Pharma Inc (SILO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Silo Pharma Inc (SILO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Silo Pharma Inc (SILO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Silo Pharma Inc (SILO) Valuation: PE, PB & Fair Value Analysis - TradingKey
Silo Pharma Inc (SILO) Institutional Confidence - TradingKey
Silo Pharma Inc (SILO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Silo Pharma Inc (SILO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
SILO PHARMA INC (SILO) Stock Chart - ChartMill
SILO Q4 2023 Earnings: EPS Misses Estimates; Pre-Revenue Biotech Faces Cash Burn ConcernsEarnings Outlook Update - newsline.com
SILO Q4 2023 Earnings: EPS Misses Estimates as Company Advances PipelineDividend Cut Risk - newsline.com
Why Did SILO Stock Soar 85% Today? - Stocktwits
Silo Pharma Implements Reverse Stock Split and Restructures Capital - The Globe and Mail
Silo Pharma Shares Drop Following Implementation of 1-for-15 Reverse Stock Split - Moomoo
Silo Pharma (SILO) completes 1-for-15 reverse stock split and cuts authorized shares - Stock Titan
Silo Pharma Announces 1-for-15 Reverse Stock Split - The Globe and Mail
Silo Pharma announces 1-for-15 reverse stock split effective June 2 - Investing.com UK
Silo Pharma announces 1-for-15 reverse stock split effective June 2 By Investing.com - Investing.com South Africa
Silo Pharma to implement 1-for-15 reverse stock split, issued shares fall to ~1.084M - TradingView
Reverse split shrinks Silo Pharma (NASDAQ: SILO) share count and authorization - Stock Titan
SILO Q4 2023 Earnings: EPS Misses Estimates as Development-Stage Biotech Maintains FocusWeak Earnings Momentum - The Legal Advocate
Silo Pharma (SILO) Holds Near Support as Biotech Stock Edges HigherDealer Delta - newsline.com
Silo Pharma Inc. (SILO) Holds Above $0.40 Support After Modest GainsShort Setup Alerts - newsline.com
Silo Pharma (SILO) Surges 5% as Small-Cap Biotech Recovers From Recent LowsSupply Zone - newsline.com
Silo Pharma Inc. (SILO) Rallies 3.99% as Biotech Sentiment Improves — Key Levels in FocusDebt Free Companies - The Legal Advocate
Silo Pharma Inc. (SILO) Q4 2023 Earnings: Widening Losses as Pre-Revenue Biotech Focuses on Pipeline ProgressProfit Margin Analysis - Newser
SILO Q4 2023 Earnings: Biotech Misses EPS Estimates as Pre‑Revenue Phase ContinuesCrowd Stock Picks - Newser
Silo Pharma Inc. (SILO) Edges Higher as Shares Test Key ResistanceAggressive Growth Picks - Newser
Silo Pharma (SILO) Q4 2023 Results Disappoint: What Investors Should KnowRevenue Miss Report - The Legal Advocate
Silo Pharma (SILO) Q4 2023 Earnings: Miss Sparks ConcernTrending Entry Points - Newser
Silo Pharma (SILO) Stock Analysis: Falls -3.79%, Watching $0.35 2026-05-19NHNL Ratio - The Legal Advocate
Silo Pharma (SILO) Q4 2023 Results Miss Estimates — EPS $-0.36 vs $-0.20Special Dividend Alert - newsline.com
Silo Pharma, Inc. (SILO) Q1 2026 10-Q: Financials, Crypto Asset Holdings, and Business Developments - Minichart
Silo Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Silo Pharma (NASDAQ: SILO) Q1 loss widens as R&D and crypto costs rise - Stock Titan
Silo Pharma Launches Ibogaine-Based TBI Therapeutics Initiative - citybuzz -
Silo Pharma files patent for ibogaine-based TBI treatment By Investing.com - Investing.com Australia
Silo Pharma files patent for ibogaine-based TBI treatment - Investing.com
With no FDA-approved TBI drugs, Silo pursues ibogaine therapy - Stock Titan
Silo Pharma Inc (SILO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.74%
1.44%
자본화:
|
볼륨(24시간):